Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
MA 02 - Emerging Targets
- 11:00 - 12:30
- 10/16/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Ravi Salgia, Shun Lu
-
+
MA 02.01 - Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors
11:00 - 11:05 | Presenter: Ticiana A. Leal | Author(s): T. Campbell, A. Mapes, K. Schneider, M.J. Staab, K. Velastegui, J.G. Christensen, I. Chen, A. Traynor
- Abstract
Loading... -
+
MA 02.02 - Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
11:05 - 11:10 | Presenter: Luis Paz-Ares | Author(s): B.P. Levy, Giuseppe Giaccone, Benjamin Besse, Enriqueta Felip, Marina Chiara Garassino, M. Domine, Pilar Garrido, B. Piperdi, S. Ponce Aix, R. Slepetis, X. Wu, A. Fandi
- Abstract
Loading... -
+
MA 02.03 - Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study
11:10 - 11:15 | Presenter: Mark Awad | Author(s): Y. Le Bruchec, R. Markelewicz, P. Chen, A. Fandi, A. Spira
- Abstract
Loading... -
+
MA 02.04 - Discussant - MA 02.01, MA 02.02, MA 02.03
11:15 - 11:30 | Presenter: Grace K Dy
- Abstract
No abstract available for this presentation
-
+
MA 02.05 - Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP)
11:30 - 11:35 | Presenter: Domenico Galetta | Author(s): A. Ardizzoni, P. Bidoli, R. Chiari, L. Bonomi, D. Turci, L. Landi, L. Toschi, M. De Tursi, G. Francini, M. Giordano, O. Alabiso, A. De Censi, L. Livi, A. Berruti, M. Minelli, E. Ricevuto, A. Illiano, G. Puppo, A. Delmonte
- Abstract
Loading... -
+
MA 02.06 - BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy
11:35 - 11:40 | Presenter: Elizabeth Dudnik | Author(s): Nir Peled, M. Wollner, Amir Onn, A. Agbareya, H. Nechushtan, T. Kuznetsov, L.C. Roisman, A. Belilovski Rozenblum, Smadar Geva, A. Zer, Jair Bar
- Abstract
Loading... -
+
MA 02.07 - A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
11:40 - 11:45 | Presenter: Aaron Lisberg | Author(s): J. Hunt, N. Reese, T. Wang, P. Coluzzi, M. Spiegel, K. Bornazyan, J. Carroll, J. Madrigal, B. Ledezma, M. Mendenhall, J.L. Bui, H. Lu, A. Cummings, Z. Noor, Jonathan W. Goldman, Edward Brian Garon
- Abstract
Loading... -
+
MA 02.08 - Discussant - MA 02.05, MA 02.06, MA 02.07
11:45 - 12:00 | Presenter: Barbara Melosky
- Abstract
No abstract available for this presentation
-
+
MA 02.09 - A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC
12:00 - 12:05 | Presenter: Don Lynn Gibbons | Author(s): L. Byers, David E Gerber, J. Peguero, D. Micklem, M. Yule, J. Lorens
- Abstract
Loading... -
+
MA 02.10 - Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
12:05 - 12:10 | Presenter: Jonathan Wade Goldman | Author(s): E. Angevin, J. Strickler, D. Ross Camidge, R. Heist, D. Morgensztern, M. Barve, H. Yue, J. Beaulieu, M. Motwani, D. Afar, L. Naumovski, Karen Kelly
- Abstract
Loading... -
+
MA 02.11 - A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
12:10 - 12:15 | Presenter: Jonathan W Riess | Author(s): Karen L Reckamp, J. Longmate, Karen Kelly, David R. Gandara, Philip Christopher Mack, E. Newman, Primo Lara
- Abstract
Loading... -
+
MA 02.12 - Discussant - MA 02.09, MA 02.10, MA 02.11
12:15 - 12:30 | Presenter: Dean A Fennell
- Abstract
No abstract available for this presentation
-
+
MS 25 - Novel Molecular Targets (KRAS/MET/Novel Fusions): Druggable or Not?
- 14:30 - 16:15
- 10/18/2017
- Location: Main Hall
- Type: Mini Symposium
- Track: Chemotherapy/Targeted Therapy
- Moderators:Rafael Rosell, Isamu Okamoto
-
+
MS 25.02 - KRAS-Targeted Therapy or Angiogenesis: Still a Viable Target?
14:50 - 15:10 | Presenter: Ravi Salgia | Author(s): I. Mambetsariev, I. Amanam, A. Nam
- Abstract
Loading...